AKTX Stock Analysis: Buy, Sell, or Hold?
AKTX - Akari Therapeutics plc ADR (0.01 USD)
$11.30
0.42 (3.86%)
▲
5d:
+4.24%
30d:
+57.38%
90d:
-23.75%
WAIT
LOW Confidence
Analysis Updated: Sep 11, 2026 12:00 AM ET
Earnings: Aug 12, 2026
0d
Get Alerted When AKTX Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
📊 MIXED SIGNALS: AKTX shows conflicting indicators. Wait for confirmation before entering.
📊 MIXED SIGNALS: AKTX shows conflicting indicators. Wait for confirmation before entering.
In-depth Analysis How we analyze
Valuation Analysis: AKTX is currently trading at $11.30, which is considered extended relative to its 30-day fair value range of $7.34 to $10.41.
Technical Outlook: Technically, AKTX is showing sideways momentum. Immediate support is located at $8.80, while resistance sits at $12.15. The stock is showing strong short-term momentum, up 3.9% recently.
Market Sentiment: AKTX scores 0/100 on our bottoming-setup gauge. Note this measures entry quality, not trend direction — a low score can mean the chart is extended after a strong run (don't chase) or still falling without stabilization; better entries typically come after a pullback toward the 20-day average. Wall Street analysts see significant upside, with an average price target of $28.50 (+152.2%). Current signals suggest waiting for a better entry point before initiating new positions.
Technical Outlook: Technically, AKTX is showing sideways momentum. Immediate support is located at $8.80, while resistance sits at $12.15. The stock is showing strong short-term momentum, up 3.9% recently.
Market Sentiment: AKTX scores 0/100 on our bottoming-setup gauge. Note this measures entry quality, not trend direction — a low score can mean the chart is extended after a strong run (don't chase) or still falling without stabilization; better entries typically come after a pullback toward the 20-day average. Wall Street analysts see significant upside, with an average price target of $28.50 (+152.2%). Current signals suggest waiting for a better entry point before initiating new positions.
Quick Decision Summary
Current Position
EXTENDED
Historical Trading Range
$7.34 -
$10.41
Company Quality Score
33/100
(SELL)
Volume Confirmation
HIGH
Confidence Score
26.3%
All Signals
- BEARISH: Price extended above range (+8.5% above its trading range)
- BEARISH: Weak technical setup (0/100)
- BULLISH: High volume confirmation
- BULLISH: Strong upward momentum (+3.9%)
- BULLISH: Trading 152.2% below Wall St target ($28.50)
- WARNING: Composite score 33/100 in the bottom quintile — this cohort historically lags the market
Trading Range Analysis
30-Day Trading Range
$7.34 -
$10.41
Current vs Trading Range
EXTENDED
Support & Resistance Levels
Support Level
$8.80
Resistance Level
$12.15
Current Trend
Sideways
Technical data as of
Sep 11, 2026
Fundamental Context
Forward P/E (Next Year Est.)
-9.70
Wall Street Target
$28.50
(+152.2%)
Share & Embed Analysis
Last updated: September 13, 2026 10:48 AM ET
Data refreshes hourly during market hours. Next update: 11:48 AM
Data refreshes hourly during market hours. Next update: 11:48 AM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is AKTX showing a specific setup today?
Insider Activity (6 Months)
0
Buys
0
Sells
0
Net
NEUTRAL
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
XENE
Xenon Pharmaceuticals Inc |
STRONG BUY
19 analysts |
$81 | 52 HOLD |
|
IONS
Ionis Pharmaceuticals Inc |
BUY
26 analysts |
$84 | 50 HOLD |
|
RARE
Ultragenyx |
STRONG BUY
20 analysts |
$27 | 49 HOLD |
|
ACLX
Arcellx Inc |
STRONG BUY
18 analysts |
$113 | 50 HOLD |
|
VKTX
Viking Therapeutics Inc |
STRONG BUY
19 analysts |
$92 | 50 HOLD |
